We’re excited to share some exciting news from the JP Morgan Healthcare Conference. Amidst the industry’s largest and most insightful investment conference, which was a whirlwind of innovation and insight, there was significant interest in Sen-Jam’s innovative anti-inflammatory products!
A crucial insight gained was the growing understanding within the broader healthcare and investor communities that our products appear uniquely positioned not only to treat but also to prevent inflammation in a markedly different way than current therapeutics. This marks a game-changing moment as addressing chronic inflammation, rather than just acute inflammation, is a massive, unmet need. Chronic inflammation affects 61% of Americans, making it a common ailment that is challenging to treat due to the concerning side effects associated with the current standard of care. Our assets stand out for their low side effects and high efficacy in treating inflammation at its root.
The attendees were most excited to learn that our assets can rapidly enter into human trials based on their safety profiles. We spoke to several companies about possible licensing deals, and we will follow up with all of them to begin building out our pipeline even more!
It’s evident that we’re on the right track, and there’s tangible excitement about what Sen-Jam is bringing to the healthcare industry. We’re poised to usher in a new era in pharma.
We are truly set to change the course of inflammation!
Curious to hear more? We’ll share a quick debrief on the conference at our webinar taking place next Thursday, January 25th. Beyond these developments, the main topic of the webinar will be demystifying Weight Loss & Inflammation: The Hot News and Insights on Ozempic. You can register here.
There was also a nice piece done two days ago in Forbes recapping the week that you can read here. Thank you for being a part of our journey. Stay tuned for more updates – the best is yet to come.